Oncotelic Therapeutics, Inc. (OTLC) are developing three lines of therapeutics. 1) Oncology/Virology - we are developing OT-101 (TGF-beta antisense/ Artemisinin) and VDA agents (Oxi4503/CA4P) against viral infections and various tumors including three rare pediatric tumors (DIPG, Melanoma, and AML).... Oncotelic Therapeutics, Inc. (OTLC) are developing three lines of therapeutics. 1) Oncology/Virology - we are developing OT-101 (TGF-beta antisense/ Artemisinin) and VDA agents (Oxi4503/CA4P) against viral infections and various tumors including three rare pediatric tumors (DIPG, Melanoma, and AML). The program is being funded by our partner GMP through a JV that we are intend to take IPO. 2) AL-101 (intranasal-apomorphine) for the treatment of Parkinson Disease, Erectile Dysfunction not responding to PDE5 inhibitor, and Female Sexual Dysfunction. 3) Animal health product including oncology (CA4P and Artemishas). 詳細を表示
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0085 | 35.5648535565 | 0.0239 | 0.036 | 0.019095 | 939999 | 0.02995642 | CS |
4 | 0.0109 | 50.6976744186 | 0.0215 | 0.036 | 0.017 | 624809 | 0.02491709 | CS |
12 | 0.004 | 14.0845070423 | 0.0284 | 0.036 | 0.017 | 337149 | 0.02396076 | CS |
26 | -0.0086 | -20.9756097561 | 0.041 | 0.044 | 0.017 | 190897 | 0.02599844 | CS |
52 | -0.0006 | -1.81818181818 | 0.033 | 0.05 | 0.017 | 146295 | 0.02973056 | CS |
156 | -0.0876 | -73 | 0.12 | 0.259 | 0.01 | 179362 | 0.07710125 | CS |
260 | -0.2076 | -86.5 | 0.24 | 0.36 | 0.01 | 184513 | 0.098835 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約